Table 1.
Target proteins potentially linked with acquisition of drug resistance at different timepoints. The experimentally investigated combinations are shown in bold.
| Cell Line | Drug | 4–8 Week | 16 Weeks |
|---|---|---|---|
| NGP-127 | Sorafenib | Phospholipase C, JNK1-2-3/MAP2K4-7 | JAK1, JAK3 |
| Sunitinib | JNK1-2-3/MAP2K4-7 | RAS, PI3K | |
| Pazopanib | Phospholipase C, Adenylate cyclase | EGFR | |
| Temsirolimus | JNK1-2-3/MAP2K4-7 | RAS | |
| Everolimus | PRKACA | PI3K | |
| SKOV-3 | Sorafenib | Akt | Phospholipase C |
| Sunitinib | Notch, Akt | EGFR, ErbB2, ADCYs | |
| Pazopanib | mTOR | ErbB3 | |
| Temsirolimus | Notch | EGFR-ErbB2 | |
| Everolimus | Notch | MAP2K6-MAP2K3 |